Kliogest 2 mg/1 mg FC tablets.
PDF Leaflet Revision Date: 14 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Hormone replacement therapy for estrogen deficiency in postmenopausal women.
Dosage (summary)
One tablet daily, preferably at the same time.
Special Populations
- Women over 65
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated during pregnancy and lactation.
Key Drug Interactions
- Anticonvulsants
- Antibiotics
- St John's wort
- Ciclosporin
- Lamotrigine
Contraindications
- Hypersensitivity to components
- Breast cancer
- Estrogen-dependent tumors
- Active liver disease
- Undiagnosed vaginal bleeding
- Venous thromboembolism
Common side effects
- Vaginal bleeding
- Breast pain
- Nausea
- Headache
- Fluid retention
Counselling Points
- Take at the same time daily
- Report any unusual bleeding
- Regular breast examinations recommended
- Avoid if pregnant or breastfeeding
Serious warnings
- Increased risk of breast cancer
- Increased risk of venous thromboembolism
- Monitor for mood changes
- Risk of endometrial hyperplasia
Important Disclaimer
The Kliogest 2 mg/1 mg FC tablets. professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
